Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Brain Neoplasms
  • Dacarbazine
  • Glioma
  • Neoplasm Recurrence, Local

abstract

  • In spite of a heavily pretreated population, including nearly half of patients having failed bevacizumab, the primary endpoint was met, suggesting that this regimen deserves further investigation. Results in bevacizumab-naive patients seemed particularly favorable, while results in bevacizumab-failing patients highlight the need to develop further treatment strategies for advanced MG. Clinical trials.gov identifier NCT00498927 (available at http://clinicaltrials.gov/ct2/show/NCT00498927).

publication date

  • February 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3548585

Digital Object Identifier (DOI)

  • 10.1093/neuonc/nos295

PubMed ID

  • 23243055

Additional Document Info

start page

  • 242

end page

  • 50

volume

  • 15

number

  • 2